Skip to main content

Table 1 Characteristics of studies included in the meta-analysis

From: Rivaroxaban versus aspirin in prevention of venous thromboembolism following total joint arthroplasty or hip fracture surgery: a meta-analysis

First author

Year

Country

Sample number (rivaroxaban/aspirin)

Average age (years) (rivaroxaban/aspirin)

Type of surgery

Intervention (rivaroxaban/aspirin)

Follow-up

Endpoints

Jiang [10]

2014

China

60/60

63.8 ± 6.7/65.1 ± 7.5

TKA

10 mg once daily, 14 days/100 mg once daily, 14 days

42 days

VTE

Zou [11]

2014

China

102/110

63.50/62.70

TKA

10 mg once daily, 14 days/100 mg once daily, 14 days

28 days

VTE, nonmajor bleeding

Colleoni [12]

2018

Brazil

18/14

67.11 ± 7.65/71.21 ± 6.35

TKA

10 mg once daily, 14 days/300 mg once daily, 14 days

90 days

VTE, all-cause mortality

Anderson (a) [4]

2018

Canada

902/902

60.90 ± 11.00/61.30 ± 11.10

THA

10 mg once daily, 30 days/81 mg once daily, 30 days

90 days

VTE, major bleeding, nonmajor bleeding, all-cause mortality

Anderson (b) [4]

2018

Canada

815/805

64.70 ± 8.40/64.60 ± 8.70

TKA

10 mg once daily, 9 days/81 mg once daily, 9 days

90 days

VTE, major bleeding, nonmajor bleeding, all-cause mortality

Lindquist [13]

2018

USA

440/360

65.4/65.8

THA or TKA

10 mg once daily, THA: 35 days, TKA: 12 days/325 mg twice daily, THA: 35 days, TKA: 12 days

30 days

major bleeding, nonmajor bleeding

Yuenyongviwat [14]

2019

Thailand

76/79

71.41 ± 6.17/70.08 ± 5.22

TKA

10 mg once daily, 14 days/100 mg once daily, 14 days

42 days

VTE, major bleeding, nonmajor bleeding

Huang [15]

2019

China

192/198

67.8 ± 16.9/69.4 ± 17.4

HFS

10 mg once daily, 14 days/100 mg once daily, 16 days

90 days

VTE, major bleeding, nonmajor bleeding

  1. TKA Total knee arthroplasty, THA Total hip arthroplasty, HFS Hip fracture surgery, VTE Venous thromboembolism, Anderson (a) the type of surgery in this study was THA, Anderson (b) the type of surgery was TKA